News on Wellness

Hay Fever Tablet Gets a Go-Ahead from FDA!

Hay Fever Tablet

Nearly 60 million American citizens have been suffering from hay fever; however, only 3 million of them are medically treated with injections. FDA said that it has certified the first hay fever medication that reduces fever symptoms. FDA also stated that this new tablet is the alternative source to monthly/weekly clinic visits and checkup for taking allergy shots.

Hay Fever Tablet

The tablet named Oralair has been given green signal by FDA and it will be prescribed to patients aged above 10 years. It has been invented by French firm Stallergenes, a leader in immunotherapy drug, which dissolves under the tongue.

The new drug has to be consumed on daily basis, and it would reduce allergic reactions to other common grass types, including Timothy, sweet vernal, perennial rye, orchard, and Kentucky bluegrass. Researchers mentioned that the tablet comprises freeze (cold) dried extras from grass pollens.

Merck & Co, drug manufacturer from Whitehouse Station, New Jersey stated that since FDA has already approved the drug, it is most likely to be in market by midyear. Merck & Co. makes immunotherapy tablets that treat grass pollen allergies and ragweed diseases. Merck & Co. is leading the drug making department of respiratory treatments and has been trading Nasonex allergy spray, Claritin allergy pills, asthma inhalers, etc.

Until now, people suffering from fever were treated with drugs that cured congestion temporarily, relieving them from sneezing, itchy eyes, running nose, etc. Oralair is proved to be effective by 16 to 30% over those dummy drugs.

The side effects could cause mouth swelling, throat irritation, or allergic reaction in some patients. Hence, the first dosage would be given at clinic to observe the potential side effects and problems.

Oralair is approved for sale across 31 nations, including Russia, Australia, Canada, and several European countries.

Leave a Reply

Your email address will not be published. Required fields are marked *